By Gwendolyn Wu
Published October 6, 2026
In a move that signals a renewed sense of urgency for the European life sciences ecosystem, the Dutch venture capital firm Forbion has successfully closed a massive 2.3 billion euro ($2.6 billion) fundraising campaign. The capital, spread across two distinct vehicles—Forbion Growth Opportunities IV and Forbion Ventures Fund VIII—represents the firm’s largest fundraising effort to date. This infusion of “dry powder” arrives at a critical juncture for a European biotechnology sector that has been increasingly eclipsed by the sheer scale of investment in the United States and the aggressive R&D expansion seen in China.
Forbion’s latest achievement is more than just a financial milestone; it is a strategic bolster for European startups struggling to secure growth capital in a tightening global market. By expanding its assets under management (AUM) to 7.5 billion euros, Forbion is positioning itself as a primary firewall against the “brain drain” and capital flight that have plagued the continent’s biotech industry over the last decade.
The Core Facts: A Record-Breaking Raise
The dual-fund structure is designed to provide comprehensive support across the lifecycle of a biotech company. The firm has confirmed that these funds possess the capacity to support as many as 30 young, high-potential companies.
The strategy behind the fundraising is twofold:
- Early-Stage Innovation: Continuing the firm’s legacy of identifying breakthrough science in its infancy.
- Growth-Stage Scaling: Providing the massive capital required for late-stage clinical trials, which often forces European companies to look toward U.S. capital markets or acquisition by Big Pharma to survive.
The fundraising process significantly exceeded the firm’s internal targets for 2026, a testament to the continued appetite from institutional investors for high-quality life sciences assets. Among the heavy hitters backing this cycle are Dutch pension managers MN and PGGM, the Kauffman Foundation, Germany’s KfW Capital, and pharmaceutical giant Eli Lilly.
Chronology of a Powerhouse
Forbion’s ascent is not a recent phenomenon but the result of a long-term, deliberate strategy. Since its inception, the firm has acted as a cornerstone of the European life sciences landscape.
- Foundational Years: Since its founding, Forbion has supported 142 companies, playing a pivotal role in bringing 21 medical products and drugs to market.
- 2022–2024: During this period, Forbion cemented its status as one of the most active investors in the sector, publicly announcing at least 55 investments.
- 2024: The firm raised $2.2 billion, a figure that was considered a record at the time. This period saw a string of successful exits, including the acquisitions of Capstan Therapeutics, Mariana Oncology, and Aiolos Bio by pharmaceutical titans.
- October 2026: The current $2.6 billion raise is finalized, marking a new high-water mark for the firm and providing a significant psychological boost to the European investment community.
Supporting Data: The Investment Landscape
Forbion’s portfolio data illustrates a clear pattern: successful translation of academic research into clinical reality. By maintaining a focus on "active" venture capital—where partners often take board seats and provide operational guidance—Forbion has managed to navigate the volatility of the biotech market better than many passive institutional funds.
Recent investments serve as a blueprint for their current strategy:
- Sling Therapeutics: A company focused on high-impact treatments for thyroid eye disease, representing the firm’s interest in specialized, high-need therapeutic areas.
- Solstice Oncology: A venture into the highly competitive but lucrative field of immuno-oncology, showcasing the firm’s commitment to cutting-edge cancer research.
The firm’s track record of successful IPOs—such as the public debut of MapLight Therapeutics—further validates their vetting process. With 21 drugs successfully brought to market, the firm has proved that European innovation, when adequately funded, can rival any region in the world.
Official Responses and Strategic Outlook
The sentiment within Forbion remains one of cautious optimism. Addressing the current climate of capital scarcity, Sander Slootweg, co-founder and managing partner of Forbion, emphasized the importance of the new funds.
"Our successful fundraising gives us significant dry powder in a market characterized by a general shortage of capital," Slootweg stated. "This is not merely about having money to spend; it is about providing the stability that European biotech leaders need to stay the course, conduct long-term research, and resist the pressure to exit prematurely."
The participation of institutional investors like MN and PGGM indicates that the "life sciences asset class" is being viewed as a long-term hedge against broader economic instability. By including pharmaceutical partners like Eli Lilly, Forbion ensures that its portfolio companies have a direct line to the commercialization expertise required to scale globally.
The Broader Implications: Europe at a Crossroads
Despite the celebratory tone surrounding Forbion’s success, the context is one of profound industry concern. The European biotech sector is currently grappling with a crisis of confidence.
The "Alarm Bells"
Last month, a coalition of nine prominent board chairs released a scathing open letter to European regulators and policymakers. Their message was blunt: Europe is losing the race to innovate. They argued that the continent has historically treated medicine "as a cost to suppress rather than one of the best investments a government can make."
The implications of this neglect are visible:
- Clinical Trial Decline: Europe is conducting a lower percentage of global clinical trials compared to its historical share.
- Regulatory Friction: Leaders pointed to the agility of the Chinese biotech sector, which has benefited from streamlined regulatory pathways and aggressive state-backed funding.
- The "Cost" Mindset: By focusing on healthcare cost-containment, European nations have inadvertently stifled the growth of the very companies that could generate the next generation of life-saving medicines and high-value jobs.
The Competitive Gap
The U.S. continues to dominate in terms of venture capital depth and market liquidity. For European startups, the path to maturity often involves moving headquarters to the U.S. or being acquired by a U.S.-based corporation. The nine board chairs warned that if Europe does not enact policy changes to incentivize R&D and simplify regulatory processes, the continent will become a "branch office" for global pharmaceutical research rather than a hub of innovation.
A Beacon of Hope
Forbion’s $2.6 billion, while substantial, is only one piece of a much larger puzzle. It serves as a necessary, though not sufficient, condition for European recovery. The firm’s ability to attract international and domestic capital proves that the science in Europe remains world-class. However, the industry experts argue that without accompanying policy shifts—such as tax incentives for R&D, more flexible drug pricing models, and a deeper integration of European capital markets—private capital alone will struggle to reverse the long-term trends.
As the industry moves into the final quarter of 2026, all eyes will be on how Forbion deploys this capital. Their success or failure in nurturing these next 30 companies will serve as a bellwether for the continent’s ability to compete in the global bio-economy. For now, the "alarm bells" are ringing, but the influx of capital provides a temporary, yet vital, silence in which real work can continue.
Whether this represents the start of a European renaissance or a brief reprieve in a larger decline remains to be seen. Forbion has placed its bet; the ball is now in the court of European policymakers.
About the Author
